Eric J. Avery

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · HemaSphere · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · Hematological Oncology · 2019 · 26 citations

Medicine, Pharmacology, Pharmacotherapy +13

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Daniel Lysák et al. · Blood · 2021 · 22 citations

Medicine, Oncology, Pharmacotherapy +13